Ouro will leverage $120 million in funding to develop novel T cell engagers with potential to reset the immune system in patients with chronic immune-mediated ...

INCHEON, Korea and TEL AVIV, Israel I January 10, 2025 I Samsung Bioepis Co., Ltd. and Teva Pharmaceutical Industries Ltd. (NYSE: and TASE: TEVA) announced ...

UTRECHT, The Netherlands and PHILADELPHIA, PA, USA I January 10, 2025 I LAVA Therapeutics N.V. (NASDAQ: LVTX, “LAVA,” “the Company”), a clinical-stage ...

Targeting toxic oligomers without binding to plaque, designed to reduce the risk of ARIA and potentially deliver enhanced outcomes for patients ...

The primary objective of this initial clinical trial is to evaluate safety and immune responses of three different dose levels and two different vaccination schedules of ARCT-2304 vaccine. Immune ...

BELTSVILLE, MD, USA I January 10, 2025 I NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing ...

SHANGHAI & SUZHOU, China & CAMBRIDGE, MA, USA I January 09, 2025 I Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced a new strategic ...

HANGZHOU, China I January 10, 2025 I Hangzhou Sciwind Biosciences Co., a pre-commercial biopharmaceutical company focusing on developing innovative ...

New Program is a Highly Potent, Fc-engineered anti-APRIL Monoclonal Antibody Specifically Designed to Address Patient Needs ...

Mean IL-1Ra expression reached and maintained target levels in synovial fluid throughout six-month follow-up period ...

NIEL, Belgium and BOSTON, MA, USA I January 9, 2025 I etherna immunotherapies NV ("etherna"), a technology platform leader pioneering mRNA and lipid-based ...

OTTAWA, Canada I January 9, 2025 I Esphera SynBio, a pre-clinical stage synthetic biology company, today announced a new project aimed at advancing ...